

Efficacy of Short Course (<4 Days) of Antibiotics for Treatment of Acute Otitis Media in Children: A Systematic Review of Randomized Controlled Trials

ANJANA GULANI, HPS SACHDEV AND *SHAMIMA QAZI

From the Department of Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, Qutab Institutional Area, New Delhi 110 016, India; and *Department of Child and Adolescent Health and Development, World Health Organization, 20 Avenue Appia, Geneva 27, CH1211, Switzerland.

Correspondence to: Prof HPS Sachdev, E-6/12 Vasant Vihar, New Delhi 110 057, India. hpssachdev@gmail.com

Received: November 8, 2008; Initial review: December 18, 2008; Accepted: March 4, 2009.

Objective: To determine the efficacy of a short course of antibiotics (<4 days) in comparison to a longer course (≥ 4 days) for the treatment of acute otitis media in children.

Data sources: Electronic databases, hand search of reviews, bibliographies of books, abstracts and proceedings of international conferences.

Review Methods: Randomized controlled trials of the empiric treatment of acute otitis media comparing antibiotic regimens of <4 days versus ≥ 4 days in children between four weeks to eighteen years of age were included. The trials were grouped by pharmacokinetic behavior of short-course antibiotics into short-acting antibiotics, parenteral ceftriaxone, and long-acting azithromycin.

Results: We reviewed 35 trials, which provided 38 analytic components. Overall, there was no evidence of an increased risk of treatment failure until one month with a

short-course of antibiotics (RR=1.06, 95% CI 0.95 to 1.17, P=0.298). Use of short-acting oral antibiotic in short-course was associated with a significantly increased risk of treatment failure (RR=2.27, 95% CI: 1.04 to 4.99). There was a slightly increased risk of treatment failure with parenteral ceftriaxone (RR=1.13, 95% CI 0.99 to 1.30). The risk of adverse effects was significantly lower with short-course regimens (RR=0.58, 95% CI: 0.48 to 0.70).

Conclusion: There is no evidence of an increased risk of treatment failure with short course of antibiotics for acute otitis media. Among the short-course regimens, azithromycin use was associated with a lower risk of treatment failure while short-acting oral antibiotics and parenteral ceftriaxone may be associated with a higher risk of treatment failure.

Key Words: Acute otitis media, Antibiotics, Children, Management, Short-course therapy, Systematic review.

Published online: 2009, September 03. PII:S097475590800653-1

Otitis media is one of the most common childhood infections, the leading cause of visits to doctors by children, and the most frequent reason children consume antibiotics or undergo surgery in developed countries(1,2). Although there is some debate regarding the utility and specific guidelines for prescribing antimicrobials in acute otitis media(2-6), these drugs are frequently employed in practice.

The optimal duration of prescribed antibiotic treatment for acute otitis media is still unclear, and

varies worldwide. Expert opinion has recommended a reduction in antimicrobial use from 10 to 5 days for the treatment of uncomplicated otitis media in children over the age of six years(7). Many narrative and systematic reviews have assessed the quality of scientific evidence to support a short course of antibiotic treatment(3,8-10). The existing World Health Organization (WHO) recommendation for antibiotic treatment of acute otitis media is to give oral cotrimoxazole or amoxicillin for five days(11). However, on the basis of recent data, the WHO now recommends antimicrobials for only three days

(instead of five days) in non-severe pneumonia(12,13). It would therefore be useful to explore the comparative efficacy of a short course of any antibiotic with a longer course of the same or another antibiotic for the empirical treatment of acute otitis media. The current systematic review was conducted to update the evidence on this subject including bacteriologic outcomes to factor for the possibility of “Pollyanna phenomenon”(14-16).

METHODS

Objectives: To determine the efficacy of a short-course of antibiotics (<4 days) in comparison to a longer course (\geq 4 days) for the treatment of acute otitis media in children. Subgroup analyses of children less than two years old, children with a perforated ear drum and children with recurrent otitis media were conducted to address concerns that these groups may have less favorable outcomes.

Types of trials: Randomized controlled trials of empiric treatment of acute otitis media, comparing two antibiotic regimens of different duration were included.

Participants: Children between the ages of four weeks and eighteen years, with a clinical diagnosis of acute otitis media and no history of immediate antibiotic use, immune deficiency, chronic disease or head and neck abnormalities.

Intervention: Empiric antibiotic therapy of a treatment arm for <4 days (short-course), and of a comparison arm for \geq 4 days (long-course). The antibiotic could be the same or different in the two treatment arms. Trials providing additional non-antibiotic interventions (analgesics, decongestants, or both) were eligible if the only difference between the treatment arms was antibiotic duration.

Outcome measures: The primary outcome was treatment failure, which included lack of clinical resolution or relapse or recurrence of acute otitis media or bacteriologic failure (wherever culture results by tympanocentesis were available) at an evaluation point until one month (31 days) after initiation of therapy. Clinical resolution meant that the presenting signs and symptoms of acute otitis media had improved or resolved. Requirement of

second antibiotic was considered as treatment failure.

Secondary outcomes were: (a) clinical or bacteriologic failure shortly after treatment, at 10 to 14 days, because this time is most reflective of the bacteriologic effect of the drug, and it is important to distinguish between relapse and a new infection (recurrence) when considering treatment failure, as a new infection can occur even when treatment was with the most effective drug(15); (b) the cumulative number of treatment failures, relapses and recurrences reported from time of diagnosis until a final evaluation point between one and three months; and (c) any adverse effects of therapy. Middle ear effusion was not classified as a treatment failure because of its documented persistence during the course of the disease, regardless of treatment. Data were however, sought on the number of children with persistent middle ear effusion at all evaluation points.

Search methods: The trials were identified by simultaneous searches of various medical databases till August 26, 2007 (search details available on request). There were no language restrictions. The title and abstract of identified trials were scanned to exclude obviously irrelevant trials. Full texts of remaining trials were retrieved and relevant articles identified. This was supplemented by hand searches of reviews, bibliographies of books and other unpublished relevant literature. Finally, donor agencies, ‘experts’ and authors of recent reviews were contacted for their knowledge of any additional trials.

Quality assessment: We assessed the quality of trials using recommended criteria for allocation concealment, loss to follow up and blinding(17).

Data abstraction: The data was abstracted in duplicate. The trials were grouped by pharmacokinetic behavior of the antibiotic used in the short-course: (i) short-acting oral antibiotics like penicillin, amoxicillin, cefaclor; (ii) oral azithromycin or other macrolides; or (iii) parenteral ceftriaxone. In ‘multi-arm’ trials, in order to examine heterogeneity characteristics, we split the ‘shared’ group into two or more groups with smaller sample

size, and included two or more (reasonably independent) comparisons(18) or analytic components.

Statistical Analysis: Data entry and analysis were done with SPSS (version 13.0) and STATA (version 9.2) softwares. The presence of bias was evaluated by funnel plot asymmetry(19), and confirmed by Begg's and Egger's methods(20,21). Pooled estimates [relative risk (RR) with 95% confidence intervals (CI)] were calculated by both fixed and random effects models but the latter was used for depiction. Formal tests of heterogeneity were performed, namely, the statistic Cochran Q and I-squared (variation in pooled estimate attributable to heterogeneity)(22). Pre-specified sensitivity and subgroup analyses (listed in results) were performed with the user written "metan" command ("by option") in STATA (version 9.2) software(20,23,24). A separate sensitivity and subgroup analyses was also attempted to assess the robustness of outcome criteria by redefining clinical resolution to include cured, but not improved symptoms. As no analytic components were identified, which were exclusively conducted in the pre-specified strata for age groups, perforated tympanic membrane, recurrent otitis media or microbiological isolates, these subgroup analyses were done separately for those trials providing disaggregated information for outcomes on these variables. The contribution of these variables to heterogeneity was also explored by meta-regression(25).

RESULTS

We identified 46 potentially eligible randomized controlled trials(26-71). Amongst these, 8 trials were excluded(26-33), as these were ineligible (**Fig. 1**). Of the 38 trials satisfying the inclusion criteria, 3 were withdrawn by outcome(34-36). We therefore finally evaluated 35 trials, which provided 38 analytic components.

These trials were primarily conducted in developed countries. Children above 12 years age were included in one trial while no trial was conducted exclusively in subjects below 2 years of age. The duration of antibiotic use in the long-course was 10 days in 33 analytic components, 7-14 days in




FIG. 1 Flow chart for selection of randomized control trials included in the meta-analysis.

2 analytic components, 7 days in 2 analytic components, and 5 days in one analytic component. In most of the analytic components (22/36; 61%), apart from symptoms and signs of acute ear inflammation, presence of middle ear effusion was stated to be an essential diagnostic criterion (details available on request).

In the short-course regimen, short-acting oral antibiotics were used in 3 trials, azithromycin in 21

and parenteral ceftriaxone in 11. Amongst the short-acting oral antibiotics group, similar antibiotics had been used in the short and long-course arms. In the 23 analytic components, which had used oral azithromycin in short-course arm, only 4 had employed macrolides in the long-course arm while the remaining had administered short-acting oral antibiotics, either amoxicillin or amoxicillin-clavunate ($n=14$), or cephalosporins ($n=5$). Amongst the parenteral ceftriaxone use in the short-course group ($n=12$), only short-acting oral antibiotics had been employed in the long-course, primarily amoxicillin or amoxicillin-clavunate ($n=9$). In 3 analytic components, information on both clinical and bacteriologic failures was available for all subjects.

Outcomes until 1 month

The funnel plot was symmetrical suggesting the absence of publication bias, which was confirmed using the Egger's ($P=0.994$) and Begg's ($P=0.763$) methods.

Overall, there was no evidence of an increased risk of treatment failure with short-course (<4 days) (**Table I, Fig.2**). On influence analysis, no single analytic component had a substantial impact on the quantification of summary relative risk. When treatment failure was redefined to include improved subjects, the risk of this outcome was significantly lower with short-course.

On sensitivity and subgroup analyses, significant ($P<0.05$) heterogeneity was evident for only two variables, namely, pharmacokinetic behavior of antibiotic used in short-course and compliance monitoring (details available on request). Use of short-acting oral antibiotic was associated with a significantly increased risk of treatment failure. The increased risk of treatment failure with parenteral ceftriaxone was not statistically significant; however, the lower confidence interval was close to 1 (**Table I**). On univariable and multivariate meta-regression, use of azithromycin in short-course and compliance monitoring were identified as significant predictors of heterogeneity (**Table II**).

Clinical treatment failure until 1 month in culture positive otitis media: There was no evidence of an

increased risk of clinical treatment failure in trials(48,61,64,70,71) providing relevant information (**Table I**). In one study(64), about two-thirds of the subjects had recurrent otitis media and the remaining persistent otitis media. However, disaggregated culture information was not provided for recurrent and persistent otitis media. As a sensitivity analysis, exclusion of this study did not alter the findings.

Bacteriologic failure until 1 month: Bacteriologic cultures from the middle ear had been performed in all subjects at recruitment and after initiation of antibiotic therapy in three analytic components only(61,63). In addition, in 4 analytic components(47,54,57), cultures were available at two time points in only a small proportion of recruited subjects. Overall, there was no evidence of an increased risk of bacteriologic failure (**Table I**). The findings were similar when both the above subgroups were analyzed separately and there was no evidence of heterogeneity in the sub-groups.

Treatment failure in high risk groups: Stratified information in high risk groups [children below 2 years of age(45,47,65,66,70), perforated ear drum(44,45,47,59), recurrent otitis media(44,47,55, 64), and specific bacterial pathogens(39,48,61,63, 64,70,71) was depicted in some trials. There was no evidence of an increased risk of treatment failure with short-course antibiotics in these high risk groups (**Table I**).

Persistent middle ear effusion: Data on persistent middle ear effusion till 1 month was available from six trials(48,51,55,66,67,71). Except one study(55), which had used parenteral ceftriaxone, other trials had prescribed azithromycin in the short-course arm. Overall, there was no evidence of an increased risk for persistent middle ear effusion (**Table I**). There was no evidence of heterogeneity ($P=0.165$) between the two subgroups. However, the risk for persistent middle ear effusion was significantly lower when azithromycin was used as the short-course antibiotic (RR=0.81, 95% CI 0.67 to 0.98, $P=0.031$; $I^2=0.0\%$).

Relapse and recurrence: Overall, there was no evidence of an increased risk for relapse or

TABLE I SUMMARY OF POOLED ANALYSES FOR ALL OUTCOMES

Outcome	No	Random effects model RR (95% CI)	<i>P</i> value	Tests for heterogeneity I ² (%) (<i>P</i> value)	<i>P</i> value for heterogeneity in subgroups
<i>Outcomes until 1 month</i>					
Overall treatment failure	38	1.06 (0.95, 1.17)	0.298	0.10 (0.468)	Not applicable
Short-course antibiotic used					
Short acting oral	3	2.27 (1.04, 4.99)	0.040	0.00 (0.561)	
Azithromycin	23	0.93 (0.79, 1.09)	0.350	0.00 (0.713)	
Parenteral ceftriaxone	12	1.13 (0.99, 1.30)	0.071	0.00 (0.464)	0.027
Treatment failure redefining subjects showing improvement as failure	28	0.83 (0.70, 0.98)	0.024	46.50 (0.004)	Not applicable
Clinical treatment failure in culture positive otitis media	5	1.05 (0.75, 1.46)	0.796	20.0 (0.287)	Not applicable
Bacteriological failure	7	0.97 (0.66, 1.44)	0.880	0.0 (0.912)	Not applicable
Persistent middle ear effusion	6	0.86 (0.72, 1.02)	>0.05	0.0 (0.457)	Not applicable
Relapse	12	0.99 (0.73, 1.34)	>0.05	0.0 (0.992)	Not applicable
Recurrence	7	1.33 (0.66, 2.7)	>0.05	0.0 (0.771)	Not applicable
<i>Treatment failure in high risk groups until 1 month</i>					
Age (years)					
< 2	5	0.87 (0.61, 1.25)	0.454	35.30 (0.186)	
> 2	5	0.96 (0.63, 1.48)	0.864	25.70 (0.250)	0.758
Perforated eardrum*					
Yes	4	0.80 (0.39, 1.63)	0.535	0.00 (0.428)	
No	1	1.31 (0.60, 2.87)	0.499	<i>Not applicable</i>	0.365
Recurrent otitis media					
Yes	4	0.70 (0.48, 1.03)	0.070	0.00 (0.992)	
No	3	1.07 (0.65, 1.76)	0.784	0.00 (0.382)	0.186
Isolated microorganisms					
<i>S. pneumoniae/H. influenzae</i>	8	1.03 (0.81, 1.33)	0.797	0.00 (0.528)	
Others	7	0.97 (0.49, 1.88)	0.916	0.00 (0.546)	1.000
<i>Outcomes at 10 to 14 days</i>					
Treatment failure	30	1.12 (0.97, 1.3)	0.130	0.00 (0.939)	Not applicable
Persistent middle ear effusion	6	1.02 (0.92, 1.14)	0.668	0.00 (0.910)	Not applicable
<i>Outcomes between one and three months</i>					
Treatment failure	3	0.84 (0.66, 1.08)	0.171	0.00 (0.379)	Not applicable
Persistent middle ear effusion	3	0.79 (0.42, 1.49)	0.469	0.00 (0.958)	Not applicable
Relapse	2	1.18 (0.72, 1.95)	0.514	0.00 (0.660)	Not applicable
Recurrence	3	0.56 (0.36, 0.85)	0.007	0.00 (0.670)	Not applicable
<i>Adverse effects</i>					
Overall	20	0.58 (0.48, 0.70)	<0.001	0.00 (0.821)	Not applicable
Diarrhea	20	0.61 (0.38, 0.97)	0.036	81.20 (<0.001)	Not applicable
Vomiting	12	0.67 (0.46, 0.98)	0.038	0.00 (0.812)	Not applicable
Rash	17	0.82 (0.58, 1.15)	0.244	0.00 (0.500)	Not applicable
Abdominal pain	9	1.32 (0.67, 2.60)	0.426	5.1 (0.392)	Not applicable

- Number of analytic components; *Outcome until 2 months.




FIG. 2 Forest plot for treatment failure until 1 month from random effects model for short-course vs long-course in relation to pharmacokinetics of antibiotic used in short-course (analytic components = 38).

recurrence until 1 month (**Table I**). There was no evidence of heterogeneity in the sub-groups according to the pharmacokinetic behavior of the antibiotic used in the short-course.

Outcomes at 10 - 14 days and at 1 -3 months

At 10-14 days, there was no evidence of an increased risk of treatment failure or of persistent middle ear effusion (**Table I**). Limited data (three trials) evaluating outcomes between 1-3 months also did not suggest an increased risk of treatment failure, relapse, recurrence or persistent middle ear effusion with short-course (**Table I**).

Adverse effects

The risk of individuals reporting adverse effects was significantly lower with short-course (**Table I**). There was no evidence of heterogeneity in the three subgroups for the number of individuals reporting adverse effects. There was a significantly lower risk of developing diarrhea and vomiting with short-course. Amongst the antibiotics used in the short-course, oral azithromycin was associated with a decreased risk of diarrhea (0.54, 95% CI 0.33 to 0.89) and rash (0.53, 95% CI 0.32 to 0.90) whereas parenteral ceftriaxone was associated with decreased risk of vomiting but an increased risk of injection site pain (single study data).

DISCUSSION

This systematic review did not document an increased risk of treatment failure until one month with a short-course of antibiotics (RR=1.06, 95% CI 0.95-1.17). On sensitivity, subgroup and meta-regression analyses, azithromycin use in short-course and compliance monitoring emerged as significant predictors of a lower risk of treatment failure. Limited data available did not suggest an increased risk of: (i) treatment failure in culture positive cases or in high risk groups, (ii) bacteriologic failure, (iii) relapse, (iv) recurrence, (v) persistent middle ear effusion until 1 month, or (vi) treatment failure or persistent middle ear effusion at earlier (10-14 days) or later (1-3 months) evaluation points. The risk of individuals reporting adverse effects was significantly lower in short-course (RR=0.58, 95% CI 0.48 - 0.70).

Strengths and limitations of analyses: This is an updated systematic review, which also incorporates relevant sensitivity, subgroup and meta-regression analyses. Non-English publications were also evaluated. There was no evidence of publication bias. The main conclusion regarding the primary outcome remained stable over a large spectrum of stratified analyses. Influence analysis did not reveal an overwhelming effect of any single trial. We also analyzed bacteriologic failure to factor for the possibility of “Pollyanna phenomenon”(14-16). Further, significant predictors of response were identified.

It would be prudent to consider the following limitations. First, a head to head comparison of different durations of the same antibiotic was done in only four trials(37-39,54). Of these, only two had compared amoxicillin. The results of the vast majority of individual trials could therefore reflect the differences in pharmacological properties of the antibiotics used in the short and long-course arms rather than the duration of drug use. Azithromycin is a long-acting drug, and in fact, the 3-day course means >7-day antibiotic influence and the 5-day course >10-day antibiotic influence. Second, interpretation is confounded by the wide variation in diagnostic and outcome criteria. Lack of stringent diagnostic criteria(72) could have resulted in treatment of children without acute otitis media. Differences in outcome may be imperceptible if assessed too early or too late. The “test of cure” end point, defined as clinical outcome 28-30 days after initiation of antimicrobial therapy, has been recommended for acute otitis media trials(15, 73). Clinical outcome was invariably measured until 14 days only, with no further follow up. Third, in only three analytic components both bacteriologic diagnosis and outcome measures were available for all subjects. This can undermine the true difference between the bacteriologic efficacies of two treatment courses because of high rate of spontaneous cure in cases of clinically diagnosed acute otitis media(15). Fourth, information on high-risk groups was limited. Fifth, majority of the trials (74% analytic components) were conducted in developed countries. However, trial site was not a significant predictor of risk of treatment failure, and thus

TABLE II META-REGRESSION ANALYSES FOR RELATIVE RISK OF PRIMARY OUTCOME (RESTRICTED MAXIMUM LIKELIHOOD METHOD)

Study characteristic	Univariable analysis		Controlling for additional variables	
	RR (95% CI); *I ²	P	RR (95% CI)	P
Study quality				
Allocation concealment (others vs adequate)	0.84 (0.52, 1.35); 0.01	0.456	1.43 (0.70, 2.91)	0.317
Attrition (>10% vs <10%)(n=36)	1.13 (0.90, 1.43); 0.05	0.291	1.03 (0.74, 1.42)	0.873
Blinding (others vs double blind)	1.16 (0.93, 1.45); 0.00	0.172	1.00 (0.64, 1.58)	0.982
Trial site (developed vs developing)	1.21 (0.89, 1.65); 0.00	0.216	1.15 (0.82, 1.63)	0.404
Short-course arm				
Other antibiotics vs oral short-acting	0.46 (0.20, 1.04); 0.00	0.062	DR	DR
Other antibiotics vs azithromycin	1.25 (1.01, 1.55); 0.00	0.045	3.31 (1.11, 9.89)	0.034
Other antibiotics vs parenteral ceftriaxone	0.85 (0.68, 1.05); 0.00	0.127	2.71 (0.93, 7.88)	0.066
Duration of long-course antibiotic (≥ 10 vs < 10 days)	0.73 (0.35, 1.50); 0.00	0.377	0.99 (0.40, 2.45)	0.982
Cointervention (no vs yes)	0.94 (0.69, 1.27); 0.00	0.668	1.11 (0.82, 1.51)	0.475
Compliance monitoring (others vs yes)	1.39 (1.05, 1.83); 0.00	0.021	1.52 (1.01, 2.28)	0.046
Intention to treat analysis (others vs yes)	1.16 (0.92, 1.47); 0.00	0.196	0.98 (0.66, 1.46)	0.924

The number of analytic components in univariate model is 38 except where specifically stated otherwise; * Proportion of residual variation due to heterogeneity, I-squared; DR – Dropped in the analysis due to collinearity; Multivariate model – number of analytic components is 36 and the proportion of residual variation due to heterogeneity, I-squared is 0.0; In the multivariate analysis, as a sensitivity exercise, on dropping the variable attrition from the model due to missing observation in 2 units, the following variable was found significant; Compliance monitoring (others vs. yes): 1.50 (1.01, 2.23); P=0.046.

extrapolation to developing country settings may be appropriate. Finally, we performed multiple analyses which increased the possibility of false positive results. The identified significant predictors of treatment failure should therefore be considered as exploratory in nature, rather than definitive.

There is a paucity of similar earlier analyses for direct comparison. A systematic review of randomized controlled trials, based on a search conducted in March 1998, compared the effectiveness of short and longcourses of antibiotic therapy; however, the definitions of short and long-course antibiotic therapy varied from this review (<7 days versus ≥7 days)(9,10). The authors concluded that five days of short-acting antibiotic is effective treatment for uncomplicated ear infections in children. In another later systematic review(3), risk differences instead of relative risks were used to compare outcomes for different antibiotic durations amongst various subgroups of antibiotics. In 3 trials comparing ceftriaxone with 7-10 days of

amoxicillin, the combined failure rate difference was 3.4% (95% CI –1.6% to 8.5%). In a comparison of <5 days of azithromycin with 7-10 days of amoxicillin-clavunate, the pooled failure rate difference was 2.1% (95% CI 0.6% to 4.8%), which was reported as not significant.

The observed comparability between short and long-courses of antibiotics is biologically plausible, on the basis of(9,10): (i) spontaneous resolution of untreated otitis media, (ii) early eradication of pathogens after 3 to 5 days of treatment(74), (iii) poorer penetration of antibiotic into the ear with continued administration as inflammation decreases(75), and (iv) treatment of children without acute otitis media because of diagnostic uncertainty. Further, pharmacological properties offer plausible explanation. Azithromycin has a high tissue to serum ratio, elevated concentration in middle ear(76), and prolonged elimination half-life. Intramuscularly administered ceftriaxone achieves high peak serum levels after 2 hours(77) and also has a prolonged

WHAT IS ALREADY KNOWN?

- Expert opinion recommends a reduction in antimicrobial use from 10 to 5 days for uncomplicated otitis media over the age of six years.

WHAT THIS STUDY ADDS?

- In comparison to a longer course (≥ 4 days) of any antibiotic treatment for otitis media, a short course (< 4 days) of long acting azithromycin was associated with a lower risk of treatment failure while a short-course of short-acting oral antibiotics and possibly parenteral ceftriaxone were associated with a higher risk of treatment failure.

half-life. However, penicillins and cephalosporins display minimal concentration dependent killing(78); the extent of bacterial killing for this group is largely dependent on the length of exposure. For time dependent agents, maintaining drug concentrations above the MIC for at least 40% of the dosing interval is the best predictor of efficacy, and the goal of dosing is to optimize the duration of exposure(78,79). This may explain the high risk of treatment failure with short-course amoxicillin or penicillin therapy.

It is difficult to explain the lower risk of treatment failure with compliance monitoring. This could represent a false positive result due to multiple testing. However, it is possible that compliance monitoring was selectively more important for the short-course arm, particularly for azithromycin.

Adverse effects are a common reason for poor patient compliance. This review documented a lower risk for individuals reporting adverse effects with short-course therapy. The risk of developing diarrhea and rash was lower with azithromycin use in short-course. Similar results have been reported earlier(80,81), resulting in better compliance with azithromycin. Parenteral ceftriaxone was associated with a reduced risk of vomiting but an increased risk of injection site pain.

On a *posthoc* analysis (univariable meta-regression for the entire data set), industry support emerged as a significant predictor of lower risk (0.73, 95% CI 0.57 to 0.94, $P=0.015$); however, with adjustment for other variables it did not remain a significant predictor (0.73, 95% CI 0.35 to 1.52, $P=0.384$). There is thus no concrete evidence on a *post hoc* analysis that industry supported trials have

biased the pooled results; however, this possibility cannot be totally excluded.

Implications for practice and policy: A reduction in the WHO advocated oral antibiotic (cotrimoxazole or amoxicillin) therapy from five to three days cannot be proposed because of the possibility of an increased risk of treatment failure. Similarly, for parenteral ceftriaxone, higher treatment failure rates cannot be confidently excluded. Administration of a parenteral drug also raises logistic challenges. Cost effectiveness(43) and concern about enhanced bacterial resistance needs evaluation although compliance may be better(43,49,59,69). Therefore, it would be difficult to propose ceftriaxone as an alternative to the current WHO recommendation.

There was no evidence of an increased risk of treatment failure with short-course oral azithromycin while adverse effects were significantly lower, especially diarrhea and rash. Earlier trials have documented that consumers prefer shorter treatment courses(82), which result in better compliance. A methodologically weak study(63) suggests that azithromycin may be a cheaper choice than clarithromycin or amoxicillin-clavulanic acid but a detailed cost-effectiveness analysis is essential. The possible disadvantages of recommending azithromycin also need consideration. These include, the logistic implications for public health programs of recommending two separate antibiotics (cotrimoxazole or amoxicillin, and azithromycin) for different respiratory tract infections, namely, pneumonia and otitis media, and concerns about enhanced bacterial resistance.

Implications for research: Future areas for research, include: (i) data in high risk groups, (ii) trials with

outcome recording for longer periods (one month or more), (iii) comparison of different treatment durations for the same antibiotic, particularly those currently recommended by the WHO, to confidently segregate the effects of therapy duration from antibiotic profile, (iv) data on bacteriologic failure and success rates, and (v) development of antibiotic resistance during follow-up.

Overall, there is no evidence of an increased risk of treatment failure until one month with a short course (<4 days) of antibiotics for treating acute otitis media in children. However, in the short-course group, long-acting azithromycin use was associated with a lower risk of treatment failure while short-acting oral antibiotics and possibly parenteral ceftriaxone may be associated with a higher risk of treatment failure. Further research is justified to explore the possibility of recommending short-course azithromycin for treatment of uncomplicated acute otitis media in individual practice or public health settings if prescribers or parents decide to use antibiotics.

ACKNOWLEDGMENTS

Dr Reinhard Wentz, Medical Informaticist and Enquiry Desk Manager, Cruciform Library, University College London, Gower Street, London, WC1E 6BT, UK, for help with the literature search including conceptualizing the search strategy and conducting the search on databases. Mr Dileep Gupta, Statistician, Sitaram Bhartia Institute of Science and Research, New Delhi, India, for help with data entry and analysis.

Contributors: AG prepared the protocol, conceptualized and applied the search strategy, retrieved the articles, extracted the data and drafted the first version of the paper. HPSS conceptualized the review, finalized the protocol, extracted data and did the statistical analysis. SAQ developed the idea for the review, finalized the protocol and helped in retrieving the articles. All the authors contributed to the drafting of the final version of the paper. AG and HPSS are the guarantors.

Funding: Department of Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland, and Sitaram Bhartia Institute of Science and Research, New Delhi, India. The funding sources had no involvement in the decision to publish the manuscript.

Competing interests: None stated.

Disclaimer: Dr Shamim A Qazi is a staff member of the World Health Organization. The author alone is responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the World Health Organization.

REFERENCES

1. Freid VM, Mukuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. *Vital Health Stat* 1998; 13: 1-23.
2. Rovers MM, Schilder AGM, Zielhuis GA, Rosenfeld RM. Otitis media. *Lancet* 2004; 363: 465-473.
3. Marcy M, Takata G, Chan LS, Shekelle P, Mason W, Wascman L, *et al.* Management of acute otitis media: evidence report/technology assessment no. 15 (prepared by the Southern California Evidence-based Practice Center under contract no. 290-97-0001). AHRQ Publication No. 01-E010. Rockville, MD: Agency for Healthcare Research and Quality, 2001.
4. Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for acute otitis media in children. *Cochrane Database Syst Rev* 2004; 1: CD 000219.
5. Rosenfeld RM, Vertrees JE, Carr J, Cipolle RJ, Uden DL, Giebink GS, *et al.* Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. *J Pediatr* 1994; 124: 355-367.
6. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, *et al.* Antibiotics for acute otitis media: A meta-analysis with individual patient data. *Lancet* 2006; 368: 1429-1435.
7. Paradise JL. Short-course antimicrobial treatment for acute otitis media. Not best for infants and young children. *JAMA* 1997; 278: 1640-1642.
8. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. *Pediatr Infect Dis J* 1997; 16: 680-695.
9. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SE, Wincott JL, Sitar DS, Klassen TP, *et al.* Treatment of acute otitis media with a shortened course of antibiotics: A meta-analysis. *JAMA* 1998; 279: 1736-1742.

10. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SEA, Wincott JL, Sitar DS, Klassen TP, *et al.* Short course antibiotics for acute otitis media. *Cochrane Database System Rev* 2000; 2: CD 001095.
11. World Health Organization. Pocketbook of hospital care for children: Guidelines for the Management of common illnesses with limited resources. Geneva: WHO; 2005. p. 162.
12. Pakistan Multicentre Amoxicillin Short Course Therapy (MASCOT) Pneumonia Study Group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double blind trial. *Lancet* 2002; 360: 835-841.
13. Agarwal G, Awasthi S, Kabra SK, Kaul A, Singhi S, Walter SD; ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. *BMJ* 2004; 328: 1066.
14. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The Pollyanna phenomenon". *J Pediatr* 1992; 120: 72-77.
15. Dagan R, McCracken GH. Flaws in design and conduct of clinical trials in acute otitis media. *Pediatr Infect Dis J* 2002; 21: 894-902.
16. Fox MP, Fox LM. Resolving design problems in equivalency trials. *J Pediatr* 2006; 149: 12-16.
17. Higgins JPT, Green S, eds. Assessment of study quality. *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.6 [updated September 2006]; Section 6. *In: The Cochrane Library, Issue 4.* Chichester: John Wiley & Sons; 2006.
18. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. *In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008).* The Cochrane collaboration, 2008. Available from www.Cochrane-handbook.org. Accessed on March 31, 2008.
19. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. *In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context.* London: BMJ Books 2001. p. 189-208.
20. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in STATA TM. *In: Egger M, Smith GD, Altman DG. Systematic reviews in health care: Meta-analysis in context.* London: BMJ Books; 2001. p. 347-369.
21. Steichen TJ, Egger M, Sterne JAC. sbe19.1: Tests for publication bias in meta-analysis. *Stata Technical Bulletin* 1998; 44: 3-4.
22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539-1558.
23. Harris RJ, Harbord RM, Sterne JAC. Stata Version 9 Update (Distribution Date February 19, 2007) for the Stata User Written Programme sbe24 (Bradburn MJ, Deeks JJ, Altman D. sbe24: metan - an alternative meta-analysis command. *Stata Technical Bulletin* 1999; 44: 4-15). <http://fmwww.bc.edu/RePEc/bocode/m>. Accessed on March 24, 2007.
24. Tables. Human Development Report 2006, United Nations Development Programme. http://hdr.undp.org/hdr2006/pdfs/report/HDR_2006_Tables.pdf. Accessed on August 26, 2007.
25. Harbord R, Steichen T, Sharp SJ. 2004. "metareg: update to Stata module to perform meta-analysis regression" (Sharp SJ. sbe23: Meta-analysis regression. *Stata Technical Bulletin* 1998; 42: 16-22). Statistical Software Components S4446201, Boston College Department of Economics, revised 02 Feb 2005. <http://ideas.repec.org/c/boc/bocode/s446201.html>. Accessed March 15, 2007.
26. Stickler GB, Sasano JR, Mcbean JB. Treatment of acute otitis media in children: Clinical trial. *Clin Pediatr (Phila)* 1963; 2: 534-540.
27. Stickler GB, Mcbean JB. The treatment of acute otitis media in children. II. A second clinical trial. *JAMA* 1964; 187: 85-89.
28. Rubenstein MM, Mcbean JB, Hedgecock LD, Stickler GB. The treatment of acute otitis media in children. 3. A third clinical trial. *Am J Dis Child* 1965; 109: 308-313.
29. Sederberg-Olsen J. Penicillin therapy for acute otitis media in children. How long should treatment continue? *Ugeskr Laeger* 1983; 145: 1201-1204.
30. Baba S, Murai K, Kinoshita H, Kawai T, Koyama K, Tsukiyama M, *et al.* [Double-blind comparative trial of cefroxadine and cephalexin in the treatment of acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media] *Jpn J Antibiot* 1983; 36: 2595-2634.

31. Baba S, Mori Y, Suzuki K, Unno T, Kawabori S, Yanai T, *et al.* Evaluation of the efficacy of ceftriaxone in acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media. A comparative study with cefotiam as the control. *Jpn J Antibiot* 1989; 42: 212-247.
32. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. *J Antimicrob Chemother* 1993; 31 (Suppl E): 137-146.
33. Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. *J Antimicrob Chemother* 1996; 37(Suppl C): 71-81.
34. Bain J, Murphy E, Ross F. Acute otitis media: Clinical course among children who received a short course of high dose antibiotic. *BMJ (Clin Res Ed)* 1985; 91: 1243-1246.
35. Jones R, Bain J. Three-day and seven-day treatment in acute otitis media: A double-blind antibiotic trial. *J R Coll Gen Pract* 1986; 36: 356-358.
36. Gehanno P, Taillebe M, Denis P, Jacquet P, Hoareau J, Gojon D, *et al.* Short- course cefotaxime compared with five-day co-amoxycylav in acute otitis media in children. *J Antimicrob Chemother* 1990; 26 (Suppl A): 29-36.
37. Chaput de Saintongue DM, Levine DF, Temple Savage I, Burgess GW, Sharp J, Mayhew SR, *et al.* Trial of three-day and ten-day courses of amoxicillin in otitis media. *BMJ* 1982; 284: 1078-1081.
38. Meistrup-Larsen KI, Sorensen H, Johnsen NJ, Thomsen J, Mygind N, Sederberg-Olsen J. Two versus seven days penicillin treatment for acute otitis media. A placebo controlled trial in children. *Acta Otolaryngol* 1983; 96: 99-104.
39. Puczynski MS, Stankiewicz JA, O'Keefe JP. Single dose amoxicillin treatment of acute otitis media. *Laryngoscope* 1987; 97: 16-18.
40. Varsano I, Frydman M, Amir J, Alpert G. Single intramuscular dose of ceftriaxone as compared to 7-day amoxicillin therapy for acute otitis media in children. A double-blind clinical trial. *Chemotherapy* 1988; 34 (Suppl 1): 39-46.
41. Pestalozza G, Cioce C, Facchini M. Azithromycin in upper respiratory tract infections clinical trial in children with otitis media. *Scand J Infect Dis* 1992; 83: 22-25.
42. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. *J Antimicrob Chemother* 1993; 31 (Suppl E): 65-71.
43. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. *Pediatrics* 1993; 91: 23-30.
44. Mohs E, Rodriguez-Solares A, Rivas E, el Hoshy Z. A comparative study of azithromycin and amoxicillin in paediatric patients with acute otitis media. *J Antimicrob Chemother* 1993; 31 (Suppl E): 73-79.
45. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. *J Antimicrob Chemother* 1993; 31 (Suppl E): 81-88.
46. Chamberlain JM, Boenning DA, Waisman Y, Ochsenschlager DW, Klein BL. Single-dose ceftriaxone versus 10 days of cefaclor for otitis media. *Clin Pediatr (Phila)* 1994; 33: 642-646.
47. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with acute otitis media. *Eur J Clin Microbiol Infect Dis* 1995; 14: 669-676.
48. Arguedas A, Loaiza C, Herrera M, Mohs E. Comparative trial of 3-day azithromycin versus 10-day amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. *Int J Antimicrob Agents* 1996; 6: 233-238.
49. Bauchner H, Adams W, Barnett E, Klein J. Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. *Arch Pediatr Adolesc Med* 1996; 150: 396-399.
50. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. *J Antimicrob Chemother* 1996; 37 (Suppl C): 63-69.
51. Arguedas A, Loaiza C, Rodriguez F, Herrera ML, Mohs E. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. *J Chemother* 1997; 9: 44-50.
52. Barnett ED, Teele DW, Klein JO, Cabral HJ, Kharasch SJ. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media. Greater Boston Otitis Media Study Group.

- Pediatrics 1997; 99: 23-28.
53. Celik O, Gok U, Yalcin S, Karlidag T, Susaman N, Cetinkaya T. Comparison of the clinical efficacy of azithromycin and cerufoxime axetile in the treatment of patients with acute otitis media. *Mikrobiyol Bul* 1997; 31: 253-261.
 54. Ficnar B, Huzjak N, Oreskovic K, Matrapazovski M, Klinar I. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. *Croatian Azithromycin Study Group. J Chemother* 1997; 9: 38-43.
 55. Varsano I, Volovitz B, Horev Z, Robinson J, Laks Y, Rosenbaum I, *et al.* Intramuscular ceftriaxone compared with oral amoxicillin-clavulanate for treatment of acute otitis media in children. *Eur J Pediatr* 1997; 156: 858-863.
 56. De J, De M, Aristegui J, Rodrigo C, Del C, Borque C, *et al.* International multicenter study comparing azithromycin and amoxicillin-clavulinemic acid in the treatment of pediatric acute otitis media. *Acta Pediatr Esp* 1998; 56: 350-355.
 57. Garcia Callejo FJ, Velert Vila MM, Orts Alborch MH, Pardo Mateu L, Esparcia Navarro M. Comparison of azithromycin, amoxicillin/clavulanic acid and cefaclor in the treatment of acute ENT infections. *Acta Otorrinolaringol Esp* 1998; 49: 306-312.
 58. Kara CO, Ozuer MZ, Kilic I, Yalcin AN, Ergin H. Comparison of amoxicillin with second and third generation cephalosporins in the treatment of acute otitis media. *Infezioni in Medicina* 1998; 6: 93-95.
 59. Al Ghamdi YS, El Kafrawi M, Aglan YI, Saleh MA. Efficacy of single-dose intramuscular ceftriaxone for treatment of acute otitis media in children. *Saudi Medical J* 1999; 20: 41-45.
 60. Cohen R, Navel M, Grunberg J, Boucherat M, Geslin P, Derriennic M, *et al.* One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: Clinical efficacy and change in nasopharyngeal flora. *Pediatr Infect Dis J* 1999; 18: 403-409.
 61. Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, *et al.* Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. *Antimicrob Agents Chemother* 2000; 44: 43-50.
 62. Slapak I, Hornik P, Dezort J. Azithromycin and clarithromycin: Clinical and economic comparative study in the treatment of acute otitis media in children. *Otorinolaryngol Foniatr* 2000; 49: 105-109.
 63. Kawalski H, Blacha E, Kopacz M, Mos M, Cierpiol-Tracz E, Welniak M, *et al.* Azithromycin vs. Clarithromycin and Co-amoxiclav: Clinical and economic comparison in the treatment of acute otitis media in children. *New Med* 2001; 4: 14-19.
 64. Arrieta A, Arguedas A, Fernandez P, Block SL, Emperanza P, Vargas SL, *et al.* High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. *Antimicrob Agents Chemother* 2003; 47: 3179-3186.
 65. Block SL, Arrieta A, Seible M, McLinn S, Eppes S, Murphy MJ. Single dose (30mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate (45mg/kg/day) for the treatment of uncomplicated acute otitis media. *Curr Ther Res* 2003; 64 (Suppl A): A 30-42.
 66. Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, *et al.* Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. *J Antimicrob Chemother* 2003; 52: 469-472.
 67. Oguz F, Unuvar E, Suoglu Y, Erdamar B, Dundar G, Katircioglu S, *et al.* Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin. *Int J Pediatr Otorhinolaryngol* 2003; 67: 43-51.
 68. Yamei Z, Dong P, Lu P. Efficacy and safety of one dose ceftriaxone vs. ten-day oral amoxicillin for treatment of acute otitis media in children. *Zhonghua Er Ke Za Zhi* 2003; 41: 135-138.
 69. Wang CY, Lu CY, Hsieh YC, Lee CY, Huang LM. Intramuscular ceftriaxone in comparison with oral amoxicillin-clavulanate for the treatment of acute otitis media in infants and children. *J Microbiol Immunol Infect* 2004; 37: 57-62.
 70. Arguedas A, Emperanza P, Schwartz RH, Soley C, Guevara S, Caprariis de PJ, *et al.* A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. *Pediatr Infect Dis J* 2005; 24: 153-161.
 71. Guven M, Bulut Y, Sezer T, Aladag I, Eyibilen A,

- Etikan I. Bacterial etiology of acute otitis media and clinical efficacy of amoxicillin-clavulanate versus azithromycin. *Int J Pediatr Otorhinolaryngol* 2006; 70: 915-923.
72. American Academy of Pediatrics and American Academy of Family Physicians, Clinical Practice Guidelines. Subcommittee on Management of Acute Otitis Media: Diagnosis and Management of Acute Otitis Media. *Pediatrics* 2004; 113: 1451-1465.
 73. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. *Clin Infect Dis* 1992; 15 (Suppl 1): S62-88.
 74. Howie VM, Ploussard JH. The "In Vitro Sensitivity Test"- bacteriology of middle ear exudates. *Pediatrics* 1969; 44: 940-944.
 75. Canafax DM, Giebink GS. Clinical and pharmacokinetic basis for antimicrobial treatment of acute otitis media. *Otolaryngol Clin North Am* 1991; 24: 859-874.
 76. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. *J Antimicrob Chemother* 1996; 37 (Suppl C): 53-61.
 77. Fraschini F, Braga PC, Scarpazza G, Scaglione F, Pignataro O, Sambataro G, *et al.* Human pharmacokinetics and distribution in various tissues of ceftriaxone. *Chemotherapy* 1986; 32: 192-199.
 78. Rothermel CD. Single dose azithromycin for acute otitis media: A pharmacokinetic/pharmacodynamic rationale. *Curr Ther Res* 2003; 64 (Suppl A): A4-15.
 79. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998; 26: 1-10.
 80. Hopkins S. Clinical safety and tolerance of azithromycin in children. *J Antimicrob Chemother* 1993; 31 (Suppl E): 111-117.
 81. Hoepelman IM, Schneider MME. Azithromycin: the first of the tissue-selective azalides. *Int J Antimicrob Agents* 1995; 5: 145-167.
 82. Becker MH, Drachman RH, Kirscht JP. Predicting mothers' compliance with pediatric medical regimens. *J Pediatr* 1972; 81: 843-854.
-